Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PI-273||PI-273 is a small molecule that binds to and inhibits PI4KII-alpha, potentially resulting in decreased proliferation and increased apoptosis of tumor cells, and reduced tumor growth (PMID: 28827373).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|HRAS mutant||breast cancer||decreased response||PI-273||Preclinical - Cell culture||Actionable||In a preclinical study, breast cancer cell lines harboring RAS mutations, including HRAS-mutant cell lines, demonstrated decreased sensitivity to growth inhibition by PI-273, in culture (PMID: 28827373).||28827373|
|Unknown unknown||breast cancer||not applicable||PI-273||Preclinical - Cell line xenograft||Actionable||In a preclinical study, PI-273 induced cell-cycle arrest and apoptosis and decreased proliferation in breast cancer cell lines with wild-type RAS in culture, and inhibited tumor growth in a xenograft model (PMID: 28827373).||28827373|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|